A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib.

Trial Profile

A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Perifosine (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 10 Dec 2013 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Mar 2013 A significant between-group difference in progression-free survival (primary endpoint) was unlikely according to a pre-planned interim analysis conducted by the independent Data Safety and Monitoring Board. No safety concerns were raised.
    • 11 Mar 2013 Status changed from recruiting to discontinued based on information reported in an AEterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top